CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – ...

On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts ...

On November 25, Oppo is about to drop a new phone series – dubbed Reno 13 – plus, another tablet. It's called Oppo Pad 3 and ...

Jill Saunders - Actor ...

SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

Recraft, the AI lab behind the viral Red Panda model, might be one of the most powerful platforms for generative image ...

A2 Bio also shared posters highlighting early safety and biomarker data from the ongoing EVEREST ... The Tmod™ platform provides selective killing of tumor cells and protection of normal cells via a ...

Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today ...